Unadjusted 1-year risk of study outcomes for baseline anticoagulant users and nonusers
| Baseline anticoagulant users | Baseline anticoagulant nonusers | p-value | |
| Subjects | 32 | 592 | |
| Disease progression composite outcome# | 14 (43.8) | 231 (39.0) | 0.5936 |
| All-cause mortality | 5 (15.6) | 27 (4.6) | 0.0057 |
| FVC (absolute) decrease ≥10% | 3 (9.4) | 61 (10.3) | 0.8660 |
| 6MWD decrease ≥150 m | 6 (18.8) | 143 (24.2) | 0.4848 |
| All-cause mortality | 5 (15.6) | 37 (6.3) | 0.0039 |
| IPF-related mortality | 5 (15.6) | 23 (3.9)+ | 0.0018 |
| FVC % pred change observed from baseline on the visit prior to death | –4.2±5.96 | –14.6±7.68 | |
| Time to mortality¶ weeks | 25.6±9.78 | 30.8±14.57 | |
| FVC change | |||
| Absolute decrease ≥10% | 6 (18.8) | 107 (18.1) | 0.9230 |
| Relative decrease ≥10% | 11 (34.4) | 174 (29.4) | 0.5477 |
| FVC % pred change observed | –6.0±6.4§ | –5.2±6.9ƒ | 0.5274 |
| 6MWD decrease ≥50 m | 8 (25.0) | 158 (26.7) | 0.8332 |
| All-cause hospitalisation | 7 (21.9) | 112 (18.9) | 0.6784 |
Data are presented as n, n (%) or mean±sd, unless otherwise stated. FVC: forced vital capacity; 6MWD: 6-min walk distance; IPF: idiopathic pulmonary fibrosis. #: only the first disease progression event was counted for each patient; ¶: time to death from trial initiation; +: causes of non-IPF-related death were cardiac arrest (2.7%), acute cor pulmonale (2.7%), haemorrhagic stroke (2.7%), central nervous system metastases (2.7%), myocardial infarction (2.7%), small cell lung cancer (2.7%) and unknown cause (8.1%); §: n=26; ƒ: n=523.